Arcion to move topical neuropathy drug into Phase III
This article was originally published in Scrip
Executive Summary
Arcion Therapeutics is set to progress its painful diabetic neuropathy (PDN) candidate, ARC-4558 (clonidine hydrochloride 0.1% topical gel), into Phase III development after reporting mixed top-line results from its Phase IIb study.